Literature DB >> 23616222

Spontaneous remission of 2-chlorodeoxyadenosine (2-CdA)-related secondary myelodysplastic syndrome in a patient with refractory Langerhans cell histiocytosis.

Daisuke Suzuki1, Ryoji Kobayashi, Hirozumi Sano, Kenji Kishimoto, Kazue Yasuda, Masanori Nakanishi, Tetsuro Nagashima, Kunihiko Kobayashi.   

Abstract

Langerhans cell histiocytosis (LCH) is sometimes resistant to conventional chemotherapies, and treatment with 2-chlorodeoxyadenosine (2-CdA) is gaining importance as a salvage treatment for refractory or recurrent LCH. Secondary malignancies such as acute myelogenous leukemia and myelodysplastic syndrome (MDS) due to 2-CdA have recently been reported. However, there have been no reports to date of cases of 2-CdA-related secondary MDS in which spontaneous remission was achieved. Here, we report the case of a 1-year-old boy with an occipital tumor who was diagnosed with LCH by biopsy and underwent chemotherapy. However, the disease relapsed and became refractory to chemotherapy. He received 2-CdA treatment, which was effective. However 6 months after the start of treatment, he developed MDS with chromosomal abnormality of 7q-. After 1-year observation without any intervention, his hematological findings had returned to normal, and the chromosomal abnormality had also disappeared. To our knowledge, this is the first report of 2-CdA-related MDS with spontaneous hematological remission.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23616222     DOI: 10.1007/s12185-013-1343-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

1.  Cladribine for Waldenström's macroglobulinaemia.

Authors:  A Delannoy; E Van Den Neste; J L Michaux; A Bosly; A Ferrant
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

2.  Imatinib mesylate for cerebral Langerhans'-cell histiocytosis.

Authors:  Liliana Montella; Luigi Insabato; Giovannella Palmieri
Journal:  N Engl J Med       Date:  2004-09-02       Impact factor: 91.245

3.  Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA)

Authors:  S H Kroft; M S Tallman; J M Shaw; M Thangavelu; L C Peterson
Journal:  Leukemia       Date:  1997-01       Impact factor: 11.528

4.  The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society.

Authors:  R M Egeler; J P Neglia; M Aricò; B E Favara; A Heitger; M E Nesbit; H S Nicholson
Journal:  Hematol Oncol Clin North Am       Date:  1998-04       Impact factor: 3.722

5.  Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.

Authors:  L R Kong; C F Huang; D Hakimian; D Variakojis; L Klein; T M Kuzel; L I Gordon; C Zanzig; E Wollins; M S Tallman
Journal:  Cancer       Date:  1998-03-01       Impact factor: 6.860

6.  Myelodysplastic syndrome with biclonal monosomy 7 and trisomy 8 after treatment with cladribine (2-chloro-2-deoxyadenosine) and involved field radiation therapy.

Authors:  F M Laurencet; G B Zulian; C Cabrol; D C Betticher
Journal:  Cancer Genet Cytogenet       Date:  1997-11

7.  Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain.

Authors:  Kayo Yamada; Masahiro Yasui; Akihisa Sawada; Masami Inoue; Masahiro Nakayama; Keisei Kawa
Journal:  Pediatr Blood Cancer       Date:  2011-03-07       Impact factor: 3.167

8.  Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature.

Authors:  Gerald Jäger; Gerald Höfler; Werner Linkesch; Peter Neumeister
Journal:  Haematologica       Date:  2004-04       Impact factor: 9.941

9.  2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.

Authors:  Sheila Weitzman; Jorge Braier; Jean Donadieu; R Maarten Egeler; Nicole Grois; Stephan Ladisch; Ulrike Pötschger; David Webb; James Whitlock; Robert J Arceci
Journal:  Pediatr Blood Cancer       Date:  2009-12-15       Impact factor: 3.167

10.  Transient myelodysplastic syndrome associated with isochromosome 7q abnormality.

Authors:  Elaine W Leung; Richard C Woodman; Birgitte Roland; Mohamed Abdelhaleem; Melvin H Freedman; Yigal Dror
Journal:  Pediatr Hematol Oncol       Date:  2003 Oct-Nov       Impact factor: 1.969

View more
  1 in total

1.  Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis.

Authors:  Victoria V Grunwald; Marcus Hentrich; Xaver Schiel; Annika Dufour; Stephanie Schneider; Michaela Neusser; Marion Subklewe; Michael Fiegl; Wolfgang Hiddemann; Karsten Spiekermann; Maja Rothenberg-Thurley; Klaus H Metzeler
Journal:  Blood Adv       Date:  2019-09-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.